Clinical Trial Update: Safety and Efficiency Study of CD19-PD1-CART Cell in Relapsed/Refractory B Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating CD19-PD1-CART Cell therapy for relapsed/refractory B cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma B-cell

Drugs mentioned

• CD19-PD1-CART Cell

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: Lymphoma, B-Cell | Phase 2 | Status: UNKNOWN